J.P. Morgan 2020: What To Watch For At The Industry’s Biggest Meeting
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
You may also be interested in...
Zolgensma shows that a gene therapy can be a commercial hit - but there's still plenty to be wary of in this cutting-edge field.
Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.